Other hematological malignancies, such as hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) and HMA-relapsed AML, have also shown stable disease (SD) that was significantly correlated to improved OS when treated with SMO inhibitors, suggesting that SMO inhibition may add to HMA efficacy [168,171]. The gene discussed is SMO; the disease is myelodysplastic syndrome.